An observational study in Arthritis, Rheumatoid, Spondyloarthritis and Inflammatory Rheumatisms, sponsored by Nantes University Hospital. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-21.
Sponsored by Nantes University Hospital · Observational
Among 357 studies in Arthritis, Rheumatoid with a site in France — 42 open to participants now, 62 under way, 6 of them phase 3. Arthritis, Rheumatoid · France.
Among the 357 studies in Arthritis, Rheumatoid with a site in France, this one is the 39th largest by enrollment of the 134 observational ones, is one of 16 that started in 2017, is one of 135 observational ones, and was the 205th registered.
3,332 studies on the registry are indexed under Arthritis, Rheumatoid; 443 are open to participants now.
This study's enrollment of 572 is above the median of 176 across 1,016 observational studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →42 of the 357 studies in Arthritis, Rheumatoid with a site in France are open now, in 12 countries. Each count lists the studies.
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →357 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 16 started in 2017.
Median enrollment 167 across the 222 interventional studies, 271 across the 134 observational. Of the 261 that completed or were terminated, 99 (38%) have results posted.
174 of 357 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 195 are open to participants now.
Nantes University Hospital has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
17 of the studies in Arthritis, Rheumatoid with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
| NCT04870203Phase 3University Hospital, BordeauxCombination of Baricitinib and Anti-TNF in Rheumatoid Arthritis | 2027-03 |
| NCT07321340Centre Hospitalier Universitaire de Saint EtienneInsole Optimization for Rheumatoid Arthritis Patients | 2026-11 |
| NCT06235645University Hospital, ToursdEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound | 2026-11 |
| NCT04292067Assistance Publique - Hôpitaux de ParisCharacterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis | 2026-11 |
Among the 357 studies in Arthritis, Rheumatoid with a site in France, from their registry updates:
Fulfilling by all patients consequently seen by 6 rheumatologists in a same outpatient rheumatology clinic (in at least one month period) of a set of 6 questionnaires, including RAPID3 and pain catastrophizing scales.
Fulfilling by all patients (seen by 6 rheumatologists in a same outpatient rheumatology clinic from a university French hospital in at least one month period) of a set of 6 questionnaires including a RAPID3 score (Routine Assessment of Patient Index Data 3) and pain catastrophizing scale, as well as Pain detect and Hospital Anxiety and Depression scale questionnaires (HAD) , in ten predefined categories of disorders: rheumatoid arthritis; any spondyloarthritis; other inflammatory rheumatisms or systemic disorders; osteoarthritis of the upper part of the body; osteoarthritis of the lower part of the body; back pain and/or radiculalgia; bone disorders, including osteoporosis; tendinosis and other soft tissue conditions; peripheral neuropathy, including entrapment neuropathies; fibromyalgia and related conditions.
300 Men or women coming to the Rheumatology Department of the Nantes University Hospital with a senior rheumatologist agreeing to fulfil the set of 6 questionnaires
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
questionnaires, including RAPID3 and pain catastrophizing scales
Ranking of PCS scores according to the underlying disorders (10 predefined categories), and also ranking of RAPID-3 scores according to the underlying disorders (10 predefined categories).
Composite score: RAPID3 (0-30) and PCS (0-52) are widely used scales, suitable for routine fulfillment by outpatients.
Time frame: At least one month for each physician, and at least 30 patients in each category (whatever the physician seen).
Ranking of correlations between RAPID3 and Pain catastrophizing scale (PCS) (13 items) scores in the 10 subsets of categories listed above (from the strongest correlation to the lowest correlation)
RAPID3 (0-30) and PCS (0-52) are widely used scales, suitable for routine fulfillment by outpatients
Time frame: At least one month for each physician, and at least 30 patients in each category (whatever the physician seen).
Ran from Jul 2017 to primary completion in Jan 2018, 6 months.
Of 234 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 145. This study's 6 months is below that.
Counting every sponsor, half of 389 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.